initial public offerings (IPOs) trading on American exchanges

Thursday, July 3, 2014

Ardelyx (ARDX) began trading on the NASDAQ on 19 June 2014


Ardelyx, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of non-systemic, small molecule therapeutics that work in the gastrointestinal (GI), tract to treat cardio-renal, GI and metabolic diseases. The Company has developed a drug discovery and design platform enabling it, in a rapid and cost-efficient manner, to discover and design drug candidates. Utilizing its platform, the Company discovered and designed its product candidate, tenapanor, which in preclinical and clinical studies has consistently demonstrated the ability to reduce the absorption of dietary sodium and phosphorus, both of which are key factors in the progression of kidney disease. The Company’s product candidate, tenapanor, is a small molecule, orally administered inhibitor of NHE3, a transporter of sodium in the GI tract. It and AstraZeneca AB (AstraZeneca) has evaluated tenapanor in eight human clinical trials in over 765 individuals.

The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.


United States

Key stats and ratios

Q1 (Mar '14)2013
Net profit margin-35.92%-22.69%
Operating margin-5.43%-9.90%
EBITD margin--7.86%
Return on average assets-29.52%-16.25%
Return on average equity--

No comments:

Post a Comment